drugset / Trial / NCT01743001

Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

NCT01743001

Phase 3 Completed 226 enrolled Actelion
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Clinical study to assess the efficacy, safety, and tolerability of macitentan in subjects with Eisenmenger Syndrome.

Timeline

Start
2013-05-21
Primary completion
2016-12-01
Completion
2016-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Macitentan Other / unclassified 10 mg Oral